Why the study?
Do exogenous estrogens alter serum levels of IGFBP-3 and ALS in postmenopausal and hypogonadal GH-deficient women?
Do exogenous estrogens alter serum levels of IGFBP-3 and ALS in postmenopausal and hypogonadal GH-deficient women?
Exogenous oral estrogens suppress serum IGFBP-3 and ALS in a route- and dose-dependent manner, independent of endogenous GH status.
No takes yet. Share an insight, caveat, or question.
Oral estrogen may confound IGFBP-3/ALS interpretation; leaves open relevance for GH dosing in deficient women.
Kam et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: